메뉴 건너뛰기




Volumn 109, Issue 48, 2012, Pages 19769-19774

Most rhesus macaques infected with the CCR5-tropic SHIVAD8 generate cross-reactive antibodies that neutralize multiple HIV-1 strains

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR5; CROSS REACTING ANTIBODY; NEUTRALIZING ANTIBODY;

EID: 84870361929     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1217443109     Document Type: Article
Times cited : (63)

References (37)
  • 1
    • 56449131391 scopus 로고    scopus 로고
    • Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C
    • Binley JM, et al. (2008) Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. J Virol 82(23):11651-11668.
    • (2008) J Virol , vol.82 , Issue.23 , pp. 11651-11668
    • Binley, J.M.1
  • 2
    • 73949084963 scopus 로고    scopus 로고
    • Breadth of human immunodeficiency virus-specific neutralizing activity in sera: Clustering analysis and association with clinical variables
    • Doria-Rose NA, et al. (2010) Breadth of human immunodeficiency virus-specific neutralizing activity in sera: Clustering analysis and association with clinical variables. J Virol 84(3):1631-1636.
    • (2010) J Virol , vol.84 , Issue.3 , pp. 1631-1636
    • Doria-Rose, N.A.1
  • 3
    • 58149399396 scopus 로고    scopus 로고
    • Frequency and phenotype of human immunodeficiency virus envelope-specific B cells from patients with broadly cross-neutralizing antibodies
    • Doria-Rose NA, et al. (2009) Frequency and phenotype of human immunodeficiency virus envelope-specific B cells from patients with broadly cross-neutralizing antibodies. J Virol 83(1):188-199.
    • (2009) J Virol , vol.83 , Issue.1 , pp. 188-199
    • Doria-Rose, N.A.1
  • 4
    • 69249208675 scopus 로고    scopus 로고
    • Antibody specificities associated with neutralization breadth in plasma from human immunodeficiency virus type 1 subtype C-infected blood donors
    • Gray ES, et al. (2009) Antibody specificities associated with neutralization breadth in plasma from human immunodeficiency virus type 1 subtype C-infected blood donors. J Virol 83(17):8925-8937.
    • (2009) J Virol , vol.83 , Issue.17 , pp. 8925-8937
    • Gray, E.S.1
  • 5
    • 58149487645 scopus 로고    scopus 로고
    • Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection
    • Sather DN, et al. (2009) Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection. J Virol 83(2):757-769.
    • (2009) J Virol , vol.83 , Issue.2 , pp. 757-769
    • Sather, D.N.1
  • 6
    • 67650453747 scopus 로고    scopus 로고
    • Human immunodeficiency virus type 1 elite neutralizers: Individuals with broad and potent neutralizing activity identified by using a highthroughput neutralization assay together with an analytical selection algorithm
    • Simek MD, et al. (2009) Human immunodeficiency virus type 1 elite neutralizers: Individuals with broad and potent neutralizing activity identified by using a highthroughput neutralization assay together with an analytical selection algorithm. J Virol 83(14):7337-7348.
    • (2009) J Virol , vol.83 , Issue.14 , pp. 7337-7348
    • Simek, M.D.1
  • 7
    • 63849131879 scopus 로고    scopus 로고
    • Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals
    • Scheid JF, et al. (2009) Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature 458(7238):636-640.
    • (2009) Nature , vol.458 , Issue.7238 , pp. 636-640
    • Scheid, J.F.1
  • 8
    • 84857084577 scopus 로고    scopus 로고
    • Longitudinal analysis of early HIV-1-specific neutralizing activity in an elite neutralizer and in five patients who developed cross-reactive neutralizing activity
    • Euler Z, et al. (2012) Longitudinal analysis of early HIV-1-specific neutralizing activity in an elite neutralizer and in five patients who developed cross-reactive neutralizing activity. J Virol 86(4):2045-2055.
    • (2012) J Virol , vol.86 , Issue.4 , pp. 2045-2055
    • Euler, Z.1
  • 9
    • 79955389756 scopus 로고    scopus 로고
    • The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection
    • and the CAPRISA002 Study Team
    • Gray ES, et al.; and the CAPRISA002 Study Team (2011) The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection. J Virol 85(10):4828-4840.
    • (2011) J Virol , vol.85 , Issue.10 , pp. 4828-4840
    • Gray, E.S.1
  • 10
    • 58149487646 scopus 로고    scopus 로고
    • Continuous viral escape and selection by autologous neutralizing antibodies in drug-naive human immunodeficiency virus controllers
    • Mahalanabis M, et al. (2009) Continuous viral escape and selection by autologous neutralizing antibodies in drug-naive human immunodeficiency virus controllers. J Virol 83(2):662-672.
    • (2009) J Virol , vol.83 , Issue.2 , pp. 662-672
    • Mahalanabis, M.1
  • 11
    • 35348937119 scopus 로고    scopus 로고
    • Genetic characteristics of HIV-1 subtype C envelopes inducing cross-neutralizing antibodies
    • HIVNET 028 study team
    • Rademeyer C, et al.; HIVNET 028 study team (2007) Genetic characteristics of HIV-1 subtype C envelopes inducing cross-neutralizing antibodies. Virology 368(1):172-181.
    • (2007) Virology , vol.368 , Issue.1 , pp. 172-181
    • Rademeyer, C.1
  • 12
    • 84055181327 scopus 로고    scopus 로고
    • Rapid development of glycan-specific, broad, and potent anti-HIV-1 gp120 neutralizing antibodies in an R5 SIV/HIV chimeric virus infected macaque
    • Walker LM, et al. (2011) Rapid development of glycan-specific, broad, and potent anti-HIV-1 gp120 neutralizing antibodies in an R5 SIV/HIV chimeric virus infected macaque. Proc Natl Acad Sci USA 108(50):20125-20129.
    • (2011) Proc Natl Acad Sci USA , vol.108 , Issue.50 , pp. 20125-20129
    • Walker, L.M.1
  • 13
    • 84865096278 scopus 로고    scopus 로고
    • Pathogenicity and mucosal transmissibility of the R5-tropic simian/human immunodeficiency virus SHIV(AD8) in rhesus macaques: Implications for use in vaccine studies
    • Gautam R, et al. (2012) Pathogenicity and mucosal transmissibility of the R5-tropic simian/human immunodeficiency virus SHIV(AD8) in rhesus macaques: Implications for use in vaccine studies. J Virol 86(16):8516-8526.
    • (2012) J Virol , vol.86 , Issue.16 , pp. 8516-8526
    • Gautam, R.1
  • 14
    • 77950787447 scopus 로고    scopus 로고
    • Generation of the pathogenic R5-tropic simian/human immunodeficiency virus SHIVAD8by serial passaging in rhesusmacaques
    • Nishimura Y, et al. (2010) Generation of the pathogenic R5-tropic simian/human immunodeficiency virus SHIVAD8by serial passaging in rhesusmacaques.JVirol 84(9):4769-4781.
    • (2010) JVirol , vol.84 , Issue.9 , pp. 4769-4781
    • Nishimura, Y.1
  • 15
    • 2342625375 scopus 로고    scopus 로고
    • Induction of disease by a molecularly cloned highly pathogenic simian immunodeficiency virus/human immunodeficiency virus chimera is multigenic
    • Sadjadpour R, et al. (2004) Induction of disease by a molecularly cloned highly pathogenic simian immunodeficiency virus/human immunodeficiency virus chimera is multigenic. J Virol 78(10):5513-5519.
    • (2004) J Virol , vol.78 , Issue.10 , pp. 5513-5519
    • Sadjadpour, R.1
  • 16
    • 0030855058 scopus 로고    scopus 로고
    • Infection and pathogenicity of chimeric simian-human immunodeficiency viruses in macaques: Determinants of high virus loads and CD4 cell killing
    • Shibata R, et al. (1997) Infection and pathogenicity of chimeric simian-human immunodeficiency viruses in macaques: Determinants of high virus loads and CD4 cell killing. J Infect Dis 176(2):362-373.
    • (1997) J Infect Dis , vol.176 , Issue.2 , pp. 362-373
    • Shibata, R.1
  • 17
    • 0029018332 scopus 로고
    • Isolation and characterization of a syncytium-inducing, macrophage/ T-cell line-tropic human immunodeficiency virus type 1 isolate that readily infects chimpanzee cells in vitro and in vivo
    • Shibata R, et al. (1995) Isolation and characterization of a syncytium-inducing, macrophage/ T-cell line-tropic human immunodeficiency virus type 1 isolate that readily infects chimpanzee cells in vitro and in vivo. J Virol 69(7):4453-4462.
    • (1995) J Virol , vol.69 , Issue.7 , pp. 4453-4462
    • Shibata, R.1
  • 18
    • 73949127978 scopus 로고    scopus 로고
    • Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies
    • Seaman MS, et al. (2010) Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. J Virol 84(3):1439-1452.
    • (2010) J Virol , vol.84 , Issue.3 , pp. 1439-1452
    • Seaman, M.S.1
  • 19
    • 34249952292 scopus 로고    scopus 로고
    • Macaques infected with a CCR5-tropic simian/human immunodeficiency virus (SHIV) develop broadly reactive anti-HIV neutralizing antibodies
    • Kraft Z, et al. (2007) Macaques infected with a CCR5-tropic simian/human immunodeficiency virus (SHIV) develop broadly reactive anti-HIV neutralizing antibodies. J Virol 81(12):6402-6411.
    • (2007) J Virol , vol.81 , Issue.12 , pp. 6402-6411
    • Kraft, Z.1
  • 20
    • 0031901463 scopus 로고    scopus 로고
    • Neutralizing antibodies in sera from macaques infected with chimeric simian-human immunodeficiency virus containing the envelope glycoproteins of either a laboratory-adapted variant or a primary isolate of human immunodeficiency virus type 1
    • Montefiori DC, et al. (1998) Neutralizing antibodies in sera from macaques infected with chimeric simian-human immunodeficiency virus containing the envelope glycoproteins of either a laboratory-adapted variant or a primary isolate of human immunodeficiency virus type 1. J Virol 72(4):3427-3431.
    • (1998) J Virol , vol.72 , Issue.4 , pp. 3427-3431
    • Montefiori, D.C.1
  • 21
    • 23244434512 scopus 로고    scopus 로고
    • Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies
    • Li M, et al. (2005) Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol 79(16):10108-10125.
    • (2005) J Virol , vol.79 , Issue.16 , pp. 10108-10125
    • Li, M.1
  • 22
    • 0025267919 scopus 로고
    • Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera
    • Albert J, et al. (1990) Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera. AIDS 4(2):107-112.
    • (1990) AIDS , vol.4 , Issue.2 , pp. 107-112
    • Albert, J.1
  • 23
    • 49149118421 scopus 로고    scopus 로고
    • Autologous neutralizing humoral immunity and evolution of the viral envelope in the course of subtype B human immunodeficiency virus type 1 infection
    • Bunnik EM, Pisas L, van Nuenen AC, Schuitemaker H (2008) Autologous neutralizing humoral immunity and evolution of the viral envelope in the course of subtype B human immunodeficiency virus type 1 infection. J Virol 82(16):7932-7941.
    • (2008) J Virol , vol.82 , Issue.16 , pp. 7932-7941
    • Bunnik, E.M.1    Pisas, L.2    Van Nuenen, A.C.3    Schuitemaker, H.4
  • 24
    • 0025854294 scopus 로고
    • Homotypic antibody responses to fresh clinical isolates of human immunodeficiency virus
    • Montefiori DC, et al. (1991) Homotypic antibody responses to fresh clinical isolates of human immunodeficiency virus. Virology 182(2):635-643.
    • (1991) Virology , vol.182 , Issue.2 , pp. 635-643
    • Montefiori, D.C.1
  • 25
    • 79551518897 scopus 로고    scopus 로고
    • Characteristics of the earliest cross-neutralizing antibody response to HIV-1
    • Mikell I, et al. (2011) Characteristics of the earliest cross-neutralizing antibody response to HIV-1. PLoS Pathog 7(1):e1001251.
    • (2011) PLoS Pathog , vol.7 , Issue.1
    • Mikell, I.1
  • 26
    • 0037108952 scopus 로고    scopus 로고
    • Amino acid deletions are introduced into the V2 region of gp120 during independent pathogenic simian immunodeficiency virus/HIV chimeric virus (SHIV) infections of rhesus monkeys generating variants that are macrophage tropic
    • Imamichi H, et al. (2002) Amino acid deletions are introduced into the V2 region of gp120 during independent pathogenic simian immunodeficiency virus/HIV chimeric virus (SHIV) infections of rhesus monkeys generating variants that are macrophage tropic. Proc Natl Acad Sci USA 99(21):13813-13818.
    • (2002) Proc Natl Acad Sci USA , vol.99 , Issue.21 , pp. 13813-13818
    • Imamichi, H.1
  • 27
    • 0003633755 scopus 로고
    • Committee on Care and Use of Laboratory Animals National Institutes of Health, Bethesda, MD DHHs Publ. No. NIH 85-23, Revised Ed.
    • Committee on Care and Use of Laboratory Animals (1985) Guide for the Care and Use of Laboratory Animals (National Institutes of Health, Bethesda, MD) DHHs Publ. No. NIH 85-23, Revised Ed.
    • (1985) Guide for the Care and Use of Laboratory Animals
  • 28
    • 0033942484 scopus 로고    scopus 로고
    • Short- and long-term clinical outcomes in rhesus monkeys inoculated with a highly pathogenic chimeric simian/human immunodeficiency virus
    • Endo Y, et al. (2000) Short- and long-term clinical outcomes in rhesus monkeys inoculated with a highly pathogenic chimeric simian/human immunodeficiency virus. J Virol 74(15):6935-6945.
    • (2000) J Virol , vol.74 , Issue.15 , pp. 6935-6945
    • Endo, Y.1
  • 29
    • 10744233668 scopus 로고    scopus 로고
    • Macrophage-tropic simian/human immunodeficiency virus chimeras use CXCR4, not CCR5, for infections of rhesus macaque peripheral blood mononuclear cells and alveolar macrophages
    • Igarashi T, et al. (2003) Macrophage-tropic simian/human immunodeficiency virus chimeras use CXCR4, not CCR5, for infections of rhesus macaque peripheral blood mononuclear cells and alveolar macrophages. J Virol 77(24):13042-13052.
    • (2003) J Virol , vol.77 , Issue.24 , pp. 13042-13052
    • Igarashi, T.1
  • 30
    • 20344375938 scopus 로고    scopus 로고
    • Resting naive CD4+ T cells are massively infected and eliminated by X4-tropic simian-human immunodeficiency viruses in macaques
    • Nishimura Y, et al. (2005) Resting naive CD4+ T cells are massively infected and eliminated by X4-tropic simian-human immunodeficiency viruses in macaques. Proc Natl Acad Sci USA 102(22):8000-8005.
    • (2005) Proc Natl Acad Sci USA , vol.102 , Issue.22 , pp. 8000-8005
    • Nishimura, Y.1
  • 31
    • 33846061212 scopus 로고    scopus 로고
    • Loss of naïve cells accompanies memory CD4+ T-cell depletion during long-term progression to AIDS in Simian immunodeficiency virus-infected macaques
    • Nishimura Y, et al. (2007) Loss of naïve cells accompanies memory CD4+ T-cell depletion during long-term progression to AIDS in Simian immunodeficiency virus-infected macaques. J Virol 81(2):893-902.
    • (2007) J Virol , vol.81 , Issue.2 , pp. 893-902
    • Nishimura, Y.1
  • 32
    • 4344592775 scopus 로고    scopus 로고
    • Highly pathogenic SHIVs and SIVs target different CD4+ T cell subsets in rhesus monkeys, explaining their divergent clinical courses
    • Nishimura Y, et al. (2004) Highly pathogenic SHIVs and SIVs target different CD4+ T cell subsets in rhesus monkeys, explaining their divergent clinical courses. Proc Natl Acad Sci USA 101(33):12324-12329.
    • (2004) Proc Natl Acad Sci USA , vol.101 , Issue.33 , pp. 12324-12329
    • Nishimura, Y.1
  • 33
    • 33846087269 scopus 로고    scopus 로고
    • Efficient protein boosting after plasmid DNA or recombinant adenovirus immunization with HIV-1 vaccine constructs
    • Shu Y, et al. (2007) Efficient protein boosting after plasmid DNA or recombinant adenovirus immunization with HIV-1 vaccine constructs. Vaccine 25(8):1398-1408.
    • (2007) Vaccine , vol.25 , Issue.8 , pp. 1398-1408
    • Shu, Y.1
  • 34
    • 0036090585 scopus 로고    scopus 로고
    • Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy
    • Wei X, et al. (2002) Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother 46(6):1896-1905.
    • (2002) Antimicrob Agents Chemother , vol.46 , Issue.6 , pp. 1896-1905
    • Wei, X.1
  • 35
    • 76449108010 scopus 로고    scopus 로고
    • Neutralizing antibody titers conferring protection to macaques from a simian/human immunodeficiency virus challenge using the TZM-bl assay
    • Willey R, Nason MC, Nishimura Y, Follmann DA, Martin MA (2010) Neutralizing antibody titers conferring protection to macaques from a simian/human immunodeficiency virus challenge using the TZM-bl assay. AIDS Res Hum Retroviruses 26(1):89-98.
    • (2010) AIDS Res Hum Retroviruses , vol.26 , Issue.1 , pp. 89-98
    • Willey, R.1    Nason, M.C.2    Nishimura, Y.3    Follmann, D.A.4    Martin, M.A.5
  • 36
    • 70350320690 scopus 로고    scopus 로고
    • Mechanism of human immunodeficiency virus type 1 resistance to monoclonal antibody B12 that effectively targets the site of CD4 attachment
    • Wu X, et al. (2009) Mechanism of human immunodeficiency virus type 1 resistance to monoclonal antibody B12 that effectively targets the site of CD4 attachment. J Virol 83(21):10892-10907.
    • (2009) J Virol , vol.83 , Issue.21 , pp. 10892-10907
    • Wu, X.1
  • 37
    • 78049370371 scopus 로고    scopus 로고
    • Neutralization activity in a geographically diverse East London cohort of human immunodeficiency virus type 1-infected patients: Clade C infection results in a stronger and broader humoral immune response than clade B infection
    • Dreja H, et al. (2010) Neutralization activity in a geographically diverse East London cohort of human immunodeficiency virus type 1-infected patients: Clade C infection results in a stronger and broader humoral immune response than clade B infection. J Gen Virol 91(Pt 11):2794-2803.
    • (2010) J Gen Virol , vol.91 , Issue.PART 11 , pp. 2794-2803
    • Dreja, H.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.